SG10202109752XA - Treatment of cancer using anti-cd19 chimeric antigen receptor - Google Patents

Treatment of cancer using anti-cd19 chimeric antigen receptor

Info

Publication number: SG10202109752XA
Authority: SG; Singapore
Prior art keywords: cancer; treatment; antigen receptor; chimeric antigen; chimeric
Prior art date: 2014-04-07

Application number

Inventor

Jennifer Brogdon

John Byrd

Jason Dubovsky

Joseph Fraietta

Saar Gill

David Glass

Amy Johnson

Carl June

Saad Kenderian

Joan Mannick

Marcela Maus

Leon Murphy

Natarajan Muthusamy

David L Porter

Marco Ruella

William Raj Sellers

Mariusz Wasik

Original Assignee

Novartis Ag

Univ Pennsylvania

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-07

Filing date

2015-04-07

Publication date

2021-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53008859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202109752X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-07 Application filed by Novartis Ag, Univ Pennsylvania filed Critical Novartis Ag

2021-10-28 Publication of SG10202109752XA publication Critical patent/SG10202109752XA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/36—Immune checkpoint inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Oncology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SG10202109752X 2014-04-07 2015-04-07 Treatment of cancer using anti-cd19 chimeric antigen receptor SG10202109752XA (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US201461976396P	2014-04-07	2014-04-07
US201462007309P	2014-06-03	2014-06-03
US201462036493P	2014-08-12	2014-08-12
US201462076238P	2014-11-06	2014-11-06
US201462087888P	2014-12-05	2014-12-05
US201462097278P	2014-12-29	2014-12-29

Publications (1)

Publication Number	Publication Date
SG10202109752XA true SG10202109752XA (en)	2021-10-28

Family

ID=53008859

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201606909RA SG11201606909RA (en)	2014-04-07	2015-04-07	Treatment of cancer using anti-cd19 chimeric antigen receptor
SG10202109752X SG10202109752XA (en)	2014-04-07	2015-04-07	Treatment of cancer using anti-cd19 chimeric antigen receptor

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201606909RA SG11201606909RA (en)	2014-04-07	2015-04-07	Treatment of cancer using anti-cd19 chimeric antigen receptor

Country Status (24)

Country	Link
US (2)	US10357514B2 (en)
EP (3)	EP4406610A3 (en)
JP (3)	JP6765966B2 (en)
KR (3)	KR102487608B1 (en)
CN (2)	CN111514283A (en)
AU (3)	AU2015244039B2 (en)
CA (1)	CA2940671A1 (en)
DK (2)	DK3888674T3 (en)
ES (2)	ES2988631T3 (en)
FI (1)	FI3888674T3 (en)
HR (2)	HRP20240874T1 (en)
HU (2)	HUE066973T2 (en)
IL (4)	IL280215B (en)
LT (2)	LT3129470T (en)
MX (2)	MX395149B (en)
MY (1)	MY191608A (en)
PL (2)	PL3888674T3 (en)
PT (2)	PT3888674T (en)
RU (1)	RU2718542C2 (en)
SG (2)	SG11201606909RA (en)
SI (2)	SI3129470T1 (en)
TW (1)	TWI753848B (en)
WO (1)	WO2015157252A1 (en)
ZA (1)	ZA201605657B (en)

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10155038B2 (en)	2007-02-02	2018-12-18	Yale University	Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en)	2007-02-02	2016-02-02	Yale University	Method of de-differentiating and re-differentiating somatic cells using RNA
WO2010099205A1 (en) *	2009-02-24	2010-09-02	The Trustees Of The University Of Pennsylvania	Methods for treating progressive multifocal leukoencephalopathy (pml)
US11844720B2 (en)	2011-02-04	2023-12-19	Seed Health, Inc.	Method and system to reduce the likelihood of dental caries and halitosis
US12257272B2 (en)	2015-12-24	2025-03-25	Seed Health, Inc.	Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en)	2011-02-04	2024-04-09	Seed Health, Inc.	Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12279989B2 (en)	2011-02-04	2025-04-22	Seed Health, Inc.	Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11998479B2 (en)	2011-02-04	2024-06-04	Seed Health, Inc.	Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en)	2015-11-30	2024-04-09	Seed Health, Inc.	Method and system for reducing the likelihood of osteoporosis
US10940169B2 (en)	2015-11-30	2021-03-09	Joseph E. Kovarik	Method for reducing the likelihood of developing cancer in an individual human being
ES2776698T3 (en)	2012-12-20	2020-07-31	Purdue Research Foundation	T cells expressing a chimeric antigen receptor as cancer therapy
US9573988B2 (en)	2013-02-20	2017-02-21	Novartis Ag	Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
PL2958943T3 (en)	2013-02-20	2020-04-30	The Trustees Of The University Of Pennsylvania	Treatment of malignant neoplasm with a humanized chimeric anti-egfrviii antigen receptor
ES2769574T3 (en) *	2013-03-15	2020-06-26	Michael C Milone	Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (en)	2013-03-16	2019-03-21	諾華公司	Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
TWI672379B (en)	2013-12-19	2019-09-21	瑞士商諾華公司	Human mesothelin chimeric antigen receptors and uses thereof
US11672835B2 (en)	2013-12-20	2023-06-13	Seed Health, Inc.	Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11826388B2 (en)	2013-12-20	2023-11-28	Seed Health, Inc.	Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en)	2013-12-20	2023-12-12	Seed Health, Inc.	Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11529379B2 (en)	2013-12-20	2022-12-20	Seed Health, Inc.	Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11969445B2 (en)	2013-12-20	2024-04-30	Seed Health, Inc.	Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
EP3087101B1 (en)	2013-12-20	2024-06-05	Novartis AG	Regulatable chimeric antigen receptor
US11213552B2 (en)	2015-11-30	2022-01-04	Joseph E. Kovarik	Method for treating an individual suffering from a chronic infectious disease and cancer
US11998574B2 (en)	2013-12-20	2024-06-04	Seed Health, Inc.	Method and system for modulating an individual's skin microbiome
US12246043B2 (en)	2013-12-20	2025-03-11	Seed Health, Inc.	Topical application to treat acne vulgaris
US11642382B2 (en)	2013-12-20	2023-05-09	Seed Health, Inc.	Method for treating an individual suffering from bladder cancer
US11026982B2 (en)	2015-11-30	2021-06-08	Joseph E. Kovarik	Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US12329783B2 (en)	2013-12-20	2025-06-17	Seed Health, Inc.	Method and system to improve the health of a person's skin microbiome
US11980643B2 (en)	2013-12-20	2024-05-14	Seed Health, Inc.	Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12005085B2 (en)	2013-12-20	2024-06-11	Seed Health, Inc.	Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en)	2013-12-20	2023-12-05	Seed Health, Inc.	Probiotic to enhance an individual's skin microbiome
EP3097117B1 (en)	2014-01-21	2023-10-04	Novartis Ag	Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
DK3888674T3 (en) *	2014-04-07	2024-07-08	Novartis Ag	TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
KR102459384B1 (en)	2014-04-16	2022-10-26	주노 테라퓨틱스 게엠베하	Methods, kits and apparatus for expanding a population of cells
CN113046321A (en)	2014-04-23	2021-06-29	朱诺治疗学股份有限公司	Methods of isolating, culturing and genetically engineering immune cell populations for adoptive therapy
CA2955154C (en)	2014-07-21	2023-10-31	Novartis Ag	Treatment of cancer using a cd33 chimeric antigen receptor
EP3172237A2 (en)	2014-07-21	2017-05-31	Novartis AG	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014553A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Sortase synthesized chimeric antigen receptors
EP3712171A1 (en)	2014-08-19	2020-09-23	Novartis AG	Treatment of cancer using a cd123 chimeric antigen receptor
KR102804360B1 (en)	2014-09-17	2025-05-12	노파르티스 아게	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
RU2743657C2 (en)	2014-10-08	2021-02-20	Новартис Аг	Biomarkers predicting a therapeutic response to therapy with a chimeric antigen receptor, and use thereof
KR102727919B1 (en)	2014-10-20	2024-11-11	주노 쎄러퓨티크스 인코퍼레이티드	Methods and compositions for dosing in adoptive cell therapy
WO2016098078A2 (en) *	2014-12-19	2016-06-23	Novartis Ag	Dimerization switches and uses thereof
AU2015374296B2 (en)	2014-12-29	2021-09-02	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en)	2015-01-16	2016-07-21	Novartis Pharma Ag	Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
US20180140602A1 (en) *	2015-04-07	2018-05-24	Novartis Ag	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
HUE059218T2 (en)	2015-04-08	2022-11-28	Novartis Ag	Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
ES2948133T3 (en) *	2015-04-17	2023-08-31	Novartis Ag	Methods to improve the efficiency and expansion of cells expressing a chimeric antigen receptor
WO2016172583A1 (en)	2015-04-23	2016-10-27	Novartis Ag	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CA2988854A1 (en)	2015-05-08	2016-11-17	President And Fellows Of Harvard College	Universal donor stem cells and related methods
TWI859112B (en)	2015-07-21	2024-10-21	瑞士商諾華公司	Methods for improving the efficacy and expansion of immune cells
US10906951B2 (en)	2015-07-29	2021-02-02	Onk Therapeutics Limited	Modified natural killer cells and natural killer cell lines having increased cytotoxicity
EP3317401B1 (en)	2015-07-29	2018-10-03	Onkimmune Limited	Modified natural killer cells and natural killer cell lines having increased cytotoxicity
EP3331913A1 (en)	2015-08-07	2018-06-13	Novartis AG	Treatment of cancer using chimeric cd3 receptor proteins
CN108780084B (en)	2015-09-03	2022-07-22	诺华股份有限公司	Biomarkers predictive of cytokine release syndrome
MA44909A (en) *	2015-09-15	2018-07-25	Acerta Pharma Bv	THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR
EP3359562B1 (en)	2015-10-09	2019-12-04	Miltenyi Biotec Technology, Inc.	Chimeric antigen receptors and methods of use
EP4265633A3 (en)	2015-10-16	2024-01-24	The Trustees Of Columbia University In The City Of New York	Compositions and methods for inhibition of lineage specific antigens
EP3365026B1 (en)	2015-10-19	2021-09-22	University of Massachusetts	Anti-cancer and anti-inflammatory therapeutics and methods thereof
MX395154B (en)	2015-10-22	2025-03-25	Juno Therapeutics Gmbh	METHODS, KITS, AGENTS AND APPARATUS FOR TRANSDUCTION.
SG10202107602XA (en)	2015-11-04	2021-08-30	Univ Pennsylvania	Methods and compositions for gene editing in hematopoietic stem cells
UA126373C2 (en)	2015-12-04	2022-09-28	Новартіс Аг	COMPOSITION AND METHOD FOR IMMUNO-ONCOLOGY
MA44140A (en)	2015-12-22	2021-05-19	Dana Farber Cancer Inst Inc	CHEMERICAL ANTIGEN RECEPTOR (CAR) AGAINST MESOTHELIN AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTI-CANCER THERAPY
EP4477748A3 (en)	2015-12-28	2025-03-12	Novartis AG	Methods of making chimeric antigen receptor-expressing cells
EP3397756B1 (en)	2015-12-30	2023-03-08	Novartis AG	Immune effector cell therapies with enhanced efficacy
BR112018067679A2 (en) *	2016-03-04	2019-01-15	Novartis Ag	cells expressing multiple chimeric antigen receptor (car) molecules and their use
WO2017165683A1 (en)	2016-03-23	2017-09-28	Novartis Ag	Cell secreted minibodies and uses thereof
WO2017165869A1 (en) *	2016-03-25	2017-09-28	Trovagene, Inc.	Evaluaton of transgenes of genetically modified cells in bodily fluids
EP3439675A4 (en)	2016-04-08	2019-12-18	Purdue Research Foundation	METHODS AND COMPOSITIONS FOR T CAR LYMPHOCYTE THERAPY
JP6987390B2 (en) *	2016-04-08	2021-12-22	エモリーユニバーシティー	How to Treat Cancer and Infectious Diseases Using Cell-Based Therapies
US11446398B2 (en)	2016-04-11	2022-09-20	Obsidian Therapeutics, Inc.	Regulated biocircuit systems
US10188749B2 (en)	2016-04-14	2019-01-29	Fred Hutchinson Cancer Research Center	Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3443096B1 (en)	2016-04-15	2023-03-01	Novartis AG	Compositions and methods for selective expression of chimeric antigen receptors
US20210177896A1 (en)	2016-06-02	2021-06-17	Novartis Ag	Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CN109562127A (en) *	2016-06-03	2019-04-02	纪念斯隆-凯特琳癌症中心	Adoptive cellular therapy as early treatment selection
MX2018016330A (en) *	2016-06-27	2020-02-17	Univ California	COMBINATIONS FOR CANCER TREATMENT.
CN120285179A (en)	2016-07-15	2025-07-11	诺华股份有限公司	Treatment and prevention of cytokine release syndrome using chimeric antigen receptor in combination with kinase inhibitors
KR20230100748A (en) *	2016-07-28	2023-07-05	노파르티스 아게	Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
KR102717188B1 (en)	2016-10-07	2024-10-16	노파르티스 아게	Chimeric antigen receptors for the treatment of cancer
IL301786B1 (en) *	2016-10-28	2025-05-01	Morphosys Ag	Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
WO2018085731A2 (en) *	2016-11-03	2018-05-11	Juno Therapeutics, Inc.	Combination therapy of a t cell therapy and a btk inhibitor
WO2018098280A1 (en)	2016-11-22	2018-05-31	Dana-Farber Cancer Institute, Inc.	Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
US11590167B2 (en)	2016-12-03	2023-02-28	Juno Therapeutic, Inc.	Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
MA46963A (en)	2016-12-03	2019-10-09	Juno Therapeutics Inc	METHODS FOR DETERMINING THE DOSAGE OF CAR-T CELLS
CA3045338A1 (en)	2016-12-05	2018-06-14	Juno Therapeutics, Inc.	Production of engineered cells for adoptive cell therapy
WO2018118494A2 (en) *	2016-12-22	2018-06-28	Xiaotong Song	Use of car-modified human natural killer cells to treat cancer
JP7348063B2 (en)	2017-01-05	2023-09-20	フレッドハッチンソンキャンサーセンター	Systems and methods for improving vaccine efficacy
US11578115B2 (en)	2017-01-10	2023-02-14	The General Hospital Corporation	Chimeric antigen receptors based on alternative signal 1 domains
EP3574005B1 (en)	2017-01-26	2021-12-15	Novartis AG	Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018148224A1 (en)	2017-02-07	2018-08-16	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
MX2019010171A (en)	2017-02-27	2019-10-15	Juno Therapeutics Inc	COMPOSITIONS, MANUFACTURING ARTICLES AND METHODS RELATED TO DOSAGE IN CELLULAR THERAPY.
WO2018160731A1 (en)	2017-02-28	2018-09-07	Novartis Ag	Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EP3589295B1 (en)	2017-02-28	2024-09-11	Endocyte, Inc.	Compositions and methods for car t cell therapy
US11352434B2 (en)	2017-03-16	2022-06-07	The General Hospital Corporation	Chimeric antigen receptors targeting CD37
US20200085871A1 (en) *	2017-03-17	2020-03-19	University Of Tennessee Research Foundation	Methods of using cytotoxic t cells for treatment of autoimmune diseases
CA3054621A1 (en) *	2017-03-22	2018-09-27	Novartis Ag	Compositions and methods for immunooncology
IL269209B2 (en) *	2017-04-01	2023-11-01	Avm Biotechnology Llc	Substitution of cytotoxic preconditioning before cellular immunotherapy
TW201902493A (en) *	2017-04-03	2019-01-16	美商凱特製藥公司	Treatment with chimeric receptor T cells incorporating optimized multifunctional T cells
JP7299841B2 (en) *	2017-05-01	2023-06-28	ジュノーセラピューティクスインコーポレイテッド	Combining Cell Therapy with Immunomodulatory Compounds
BR112019023409A2 (en) *	2017-05-10	2020-06-16	Iovance Biotherapeutics, Inc.	METHODS FOR TREATING CANCER IN A PATIENT AND A HEMATOLOGICAL MALIGNITY, FOR EXPANDING TUMOR INFILTRANT LYMPHOCYTES, PERIPHERAL BLOOD LYMPHOCYTES AND INFILTRANT SPRAY LYMPHOCYTES, PROCEDURE FOR THE PREPARATION OF A POPULATION IN THE MANUFACTURE OF A POPULATION OF TUMOR INFILTRANT LYMPHOCYTES.
AU2018265258B2 (en) *	2017-05-10	2023-01-05	Pharma Cinq, Llc	Enveloped virus resistant to complement inactivation for the treatment of cancer
CN118662614A (en) *	2017-06-02	2024-09-20	朱诺治疗学股份有限公司	Articles and methods of treatment using adoptive cell therapy
WO2018232274A1 (en) *	2017-06-16	2018-12-20	City Of Hope	T-cell lymphoma treatments
KR20200021087A (en)	2017-06-22	2020-02-27	노파르티스 아게	Antibody Molecules for CD73 and Uses thereof
EP3642240A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
AU2018289572A1 (en) *	2017-06-22	2020-01-23	University Of Southern California	Combination cancer therapy using chimeric antigen receptor engineered natural killer cells as chemotherapeutic drug carriers
CN111093696B (en) *	2017-07-17	2023-10-27	詹森生物科技公司	Antigen-binding regions of anti-fibronectin type III domains and methods of using them
US11851678B2 (en)	2017-08-09	2023-12-26	Juno Therapeutics, Inc.	Methods for producing genetically engineered cell compositions and related compositions
CN109423481A (en) *	2017-08-24	2019-03-05	上海恒润达生生物科技有限公司	A kind of clearance detection method of CART cell
CA3075915A1 (en) *	2017-09-15	2019-03-21	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-cd19 immunotherapy
SG11202003096UA (en)	2017-10-02	2020-05-28	Humanigen Inc	Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
US10927168B2 (en)	2017-10-02	2021-02-23	Humanicen, Inc.	Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US10899831B2 (en)	2017-10-02	2021-01-26	Humanigen, Inc.	Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11130805B2 (en)	2017-10-02	2021-09-28	Humanigen, Inc.	Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
JP7585034B2 (en)	2017-10-18	2024-11-18	ノバルティスアーゲー	Compositions and methods for selective protein degradation
WO2019079777A1 (en) *	2017-10-20	2019-04-25	Fred Hutchinson Cancer Research Center	Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
KR20200069358A (en)	2017-10-25	2020-06-16	노파르티스 아게	Method for producing chimeric antigen receptor expressing cells
CN111542341A (en) *	2017-10-25	2020-08-14	锕医药股份有限公司	anti-CD45-based lymphocyte depletion method and its use in combination with ACT-based cancer therapy
US20210179709A1 (en)	2017-10-31	2021-06-17	Novartis Ag	Anti-car compositions and methods
US11623961B2 (en)	2017-11-01	2023-04-11	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
EP3704230B1 (en)	2017-11-01	2024-10-23	Juno Therapeutics, Inc.	Process for generating therapeutic compositions of engineered cells
US20210187024A1 (en) *	2017-11-01	2021-06-24	Nantkwest, Inc.	NK-92 Cells to Stimulate Anti-Cancer Vaccine
US11851679B2 (en)	2017-11-01	2023-12-26	Juno Therapeutics, Inc.	Method of assessing activity of recombinant antigen receptors
WO2019089848A1 (en)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Methods associated with tumor burden for assessing response to a cell therapy
CN111902159A (en)	2017-11-01	2020-11-06	朱诺治疗学股份有限公司	Chimeric antigen receptor specific for B cell maturation antigen (BCMA)
WO2019089858A2 (en)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Methods of assessing or monitoring a response to a cell therapy
CA3082570A1 (en)	2017-11-14	2019-05-23	Memorial Sloan-Kettering Cancer Center	Il-36 secreting immunoresponsive cells and uses thereof
KR20200088440A (en) *	2017-11-21	2020-07-22	노파르티스 아게	Trispecific binding molecules to tumor-associated antigens and uses thereof
TW201925782A (en) *	2017-11-30	2019-07-01	瑞士商諾華公司	BCMA-targeting chimeric antigen receptor, and uses thereof
KR102805731B1 (en) *	2017-12-01	2025-06-19	일루미나, 인코포레이티드	Method and system for determining the clonogenicity of somatic mutants
MA51210A (en) *	2017-12-01	2020-10-07	Juno Therapeutics Inc	METHODS FOR DOSING AND MODULATING GENETICALLY MODIFIED CELLS
JP2021505615A (en)	2017-12-08	2021-02-18	ジュノーセラピューティクスインコーポレイテッド	Phenotypic markers for cell therapy and related methods
MA51114A (en) *	2017-12-08	2020-10-14	Juno Therapeutics Inc	PROCESS FOR PRODUCING A COMPOSITIONS OF MODIFIED T-LYMPHOCYTES
WO2019136288A1 (en) *	2018-01-05	2019-07-11	Maxcyte, Inc.	Chronic car treatment for cancer
US11679129B2 (en) *	2018-01-12	2023-06-20	Curocell, Inc.	Enhanced immune cells using dual shRNA and composition including the same
US11311576B2 (en)	2018-01-22	2022-04-26	Seattle Children's Hospital	Methods of use for CAR T cells
SG11202007426XA (en)	2018-02-06	2020-09-29	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
US12240870B2 (en)	2018-02-23	2025-03-04	Purdue Research Foundation	Sequencing method for CAR T cell therapy
WO2019165215A1 (en) *	2018-02-26	2019-08-29	The Trustees Of The University Of Pennsylvania	Methods and compositions comprising cart and a smac mimetic
CN112262155A (en)	2018-03-14	2021-01-22	表面肿瘤学公司	Antibodies that bind to CD39 and uses thereof
US20210163620A1 (en) *	2018-04-05	2021-06-03	Brian Granda	Trispecific binding molecules against cancers and uses thereof
CA3104034A1 (en) *	2018-05-01	2019-11-07	Fred Hutchinson Cancer Research Center	Nanoparticles for gene expression and uses thereof
WO2019227003A1 (en)	2018-05-25	2019-11-28	Novartis Ag	Combination therapy with chimeric antigen receptor (car) therapies
AR126019A1 (en)	2018-05-30	2023-09-06	Novartis Ag	ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
US20210214459A1 (en)	2018-05-31	2021-07-15	Novartis Ag	Antibody molecules to cd73 and uses thereof
EP3801573A4 (en) *	2018-06-01	2022-03-02	Monash University	METHODS OF ACTIVATING CELLS VIA PTP-1B INHIBITION
EP3806962A1 (en)	2018-06-13	2021-04-21	Novartis AG	Bcma chimeric antigen receptors and uses thereof
CN112292140B (en) *	2018-06-22	2025-03-11	综合医院公司	Chimeric antigen receptor targeting CD37 and CD19
CN108949695A (en) *	2018-08-14	2018-12-07	杭州荣泽生物科技有限公司	A kind of non-virus carrier co-expresses CAR-T cell construction and its application of IL18
US20210171909A1 (en)	2018-08-31	2021-06-10	Novartis Ag	Methods of making chimeric antigen receptor?expressing cells
TWI875709B (en)	2018-08-31	2025-03-11	瑞士商諾華公司	Methods of making chimeric antigen receptor-expressing cells
WO2020077356A1 (en) *	2018-10-12	2020-04-16	Icell Gene Therapeutics Llc	CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
WO2020092839A1 (en)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
EP3873540A4 (en)	2018-10-31	2022-07-27	Mayo Foundation for Medical Education and Research	METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
US20220040229A1 (en) *	2018-10-31	2022-02-10	Humanigen, Inc.	Materials and methods for treating cancer
US12263190B2 (en)	2018-11-08	2025-04-01	Juno Therapeutics, Inc.	Methods and combinations for treatment and T cell modulation
EP3927371A1 (en)	2019-02-22	2021-12-29	Novartis AG	Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
AU2020229806A1 (en)	2019-02-25	2021-07-29	Novartis Ag	Mesoporous silica particles compositions for viral delivery
US20220168389A1 (en)	2019-04-12	2022-06-02	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en)	2019-04-24	2022-03-02	Novartis AG	Compositions and methods for selective protein degradation
EA202192964A1 (en) *	2019-04-30	2022-02-17	Мемориал Слоан-Кеттеринг Кэнсер Сентер	COMBINATION THERAPY
CN110157680A (en) *	2019-05-08	2019-08-23	浙江大学	Cell Culture Method for Improving the Efficacy and Durability of Chimeric Antigen Receptor T Cells
CR20210576A (en)	2019-05-21	2021-12-15	Novartis Ag	CD19-BINDING MOLECULES AND USES THEREOF
CN110218702B (en) *	2019-06-14	2024-02-27	博生吉医药科技(苏州)有限公司	Immune cell combination targeting CD138 and CD19 and application thereof
CN115151275A (en)	2019-08-30	2022-10-04	耶鲁大学	Compositions and methods for delivering nucleic acids to cells
WO2021053559A1 (en)	2019-09-18	2021-03-25	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN114981413A (en) *	2019-10-23	2022-08-30	昆士兰医学研究所理事会	Adoptive immunotherapy
WO2021084064A1 (en) *	2019-10-31	2021-05-06	Morphosys Ag	Sequential anti-cd19 therapy
TWI837437B (en) *	2019-11-06	2024-04-01	美商凱特製藥公司	Chimeric antigen receptor t cell therapy
WO2021092290A1 (en) *	2019-11-06	2021-05-14	Kite Pharma, Inc.	Chimeric antigen receptor t cell therapy
AR120563A1 (en)	2019-11-26	2022-02-23	Novartis Ag	CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
AR120566A1 (en)	2019-11-26	2022-02-23	Novartis Ag	CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
EP4086281A4 (en) *	2019-12-30	2024-02-14	China Immunotech (Beijing) Biotechnology Co., Ltd	IMPROVED STAR T CELL RECEPTOR AND ITS APPLICATION
CN113088540B (en) *	2020-01-08	2024-12-06	上海交通大学医学院附属瑞金医院	A GM-CSF knockdown T cell and its use
US20230073449A1 (en)	2020-01-23	2023-03-09	The Children's Medical Center Corporation	Stroma-free t cell differentiation from human pluripotent stem cells
BR112022017148A2 (en)	2020-02-27	2022-11-08	Novartis Ag	METHODS FOR PRODUCING CELLS THAT EXPRESS CHIMERIC ANTIGEN RECEPTOR
MX2022010685A (en)	2020-02-27	2022-09-23	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells.
CA3170369A1 (en)	2020-03-05	2022-04-14	Michal Shahar	Methods and compositions for treating cancer with immune cells
CN115335407B (en) *	2020-03-25	2024-08-27	北京艺妙神州医药科技有限公司	Chimeric antigen receptor binding to CD19 and uses thereof
KR20230012571A (en) *	2020-05-18	2023-01-26	크라제 메디컬 씨오 리미티드	Tumor treatment using immune effector cells
CA3186600A1 (en)	2020-06-08	2021-12-16	Janssen Biotech, Inc.	Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells
TW202216768A (en)	2020-06-22	2022-05-01	美商恩格姆生物製藥公司	Lair-1-binding agents and methods of use thereof
WO2022007938A1 (en) *	2020-07-09	2022-01-13	Nanjing Legend Biotech Co., Ltd.	Engineering gamma delta t cells with interleukin-36 for immunotherapy
US20220031751A1 (en)	2020-08-03	2022-02-03	Kyverna Therapeutics, Inc.	Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
TW202227124A (en)	2020-08-21	2022-07-16	瑞士商諾華公司	Compositions and methods for in vivo generation of car expressing cells
CN111944850B (en) *	2020-08-28	2023-03-31	澳门大学	Preparation method of cell for expressing anti-CD22 chimeric antigen receptor and PD-L1 blocking protein, expression vector and application
CA3193424A1 (en)	2020-08-31	2022-03-03	Yale University	Compositions and methods for delivery of nucleic acids to cells
CN113368262A (en) *	2020-09-03	2021-09-10	上海易慕峰生物科技有限公司	Method for obtaining intermediate result through solid tumor metastasis animal model
US20250215081A1 (en)	2020-11-06	2025-07-03	Novartis Ag	Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
AU2021401052A1 (en)	2020-12-18	2023-06-22	Century Therapeutics, Inc.	Chimeric antigen receptor systems with adaptable receptor specificity
WO2022165419A1 (en)	2021-02-01	2022-08-04	Kyverna Therapeutics, Inc.	Methods for increasing t-cell function
JP2024515793A (en)	2021-04-27	2024-04-10	ノバルティスアーゲー	Viral Vector Production System
CA3217354A1 (en)	2021-05-14	2022-11-17	Kite Pharma, Inc.	Chimeric antigen receptor t cell therapy
CN117693519A (en)	2021-05-25	2024-03-12	瓦克斯细胞生物	Monomeric mimetic-based chimeric antigen receptors and immune cells containing the same
CN118103392A (en) *	2021-07-30	2024-05-28	羿尊生物医药（浙江）有限公司	Universal T cells and their applications
WO2023021477A1 (en)	2021-08-20	2023-02-23	Novartis Ag	Methods of making chimeric antigen receptor–expressing cells
MX2024003887A (en)	2021-10-14	2024-07-09	Arsenal Biosciences Inc	Immune cells having co-expressed shrnas and logic gate systems.
WO2023081715A1 (en)	2021-11-03	2023-05-11	Viracta Therapeutics, Inc.	Combination of car t-cell therapy with btk inhibitors and methods of use thereof
EP4456927A1 (en)	2021-12-30	2024-11-06	TR1X, Inc.	Cd4t cells expressing il-10 and chimeric antigen receptors and uses thereof
WO2023172077A1 (en)	2022-03-08	2023-09-14	주식회사 박셀바이오	Pd-l1-specific chimeric antigen receptor and immune cell comprising same
EP4525899A1 (en)	2022-05-17	2025-03-26	Umoja Biopharma, Inc.	Manufacturing viral particles
WO2024026029A2 (en) *	2022-07-27	2024-02-01	Trustees Of Tufts College	Lipid nanoparticles for immunotherapy
CN115820742A (en) *	2022-08-10	2023-03-21	国睿(广州)生物科技有限公司	Method for improving transduction efficiency of NK cell lentivirus
AU2023361162A1 (en)	2022-10-11	2025-05-29	Yale University	Compositions and methods of using cell-penetrating antibodies
CN120112650A (en)	2022-10-26	2025-06-06	诺华股份有限公司	Lentiviral formulations
TW202434735A (en)	2022-11-04	2024-09-01	美商烏莫賈生物製藥股份有限公司	Particles displaying adhesion-molecule fusions
AU2023371640A1 (en)	2022-11-04	2025-05-15	Umoja Biopharma, Inc.	Lentiviral particles displaying fusion molecules and uses thereof
AU2023406926A1 (en)	2022-12-01	2025-06-26	Yale University	Stimuli-responsive traceless engineering platform for intracellular payload delivery
CN116410336B (en) *	2023-06-02	2023-09-22	云南赛元生物技术有限公司	Chimeric antigen receptor encoding nucleotide, CAR-NK cell, construction method and application thereof
KR20250052305A (en) *	2023-10-10	2025-04-18	서울대학교산학협력단	Chimeric antigen receptor-expressing natural killer cells for targeted cancer immunotherapy against pericytes in the solid tumor microenvironment and development of tumor microenvironment organoid models for therapeutic efficacy evaluation

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US44768A (en)		1864-10-18		Improvement in coftn-shellers
FR901228A (en)	1943-01-16	1945-07-20	Deutsche Edelstahlwerke Ag	Ring gap magnet system
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
EP0090505B1 (en)	1982-03-03	1990-08-08	Genentech, Inc.	Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4882282A (en)	1985-08-16	1989-11-21	Immunex Corporation	DNA sequences encoding bovine interleukin-2
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5906936A (en)	1988-05-04	1999-05-25	Yeda Research And Development Co. Ltd.	Endowing lymphocytes with antibody specificity
US6303121B1 (en)	1992-07-30	2001-10-16	Advanced Research And Technology	Method of using human receptor protein 4-1BB
US5858358A (en)	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en)	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US6534055B1 (en)	1988-11-23	2003-03-18	Genetics Institute, Inc.	Methods for selectively stimulating proliferation of T cells
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6319494B1 (en)	1990-12-14	2001-11-20	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
ES2096749T3 (en)	1990-12-14	1997-03-16	Cell Genesys Inc	CHEMICAL CHAINS FOR SIGNAL TRANSDUCTION ROADS ASSOCIATED WITH A RECEIVER.
US7049136B2 (en)	1991-03-07	2006-05-23	The General Hospital Corporation	Redirection of cellular immunity by receptor chimeras
US6004811A (en)	1991-03-07	1999-12-21	The Massachussetts General Hospital	Redirection of cellular immunity by protein tyrosine kinase chimeras
IE920716A1 (en)	1991-03-07	1992-09-09	Gen Hospital Corp	Redirection of cellular immunity by receptor chimeras
DE69233482T2 (en)	1991-05-17	2006-01-12	Merck & Co., Inc.	Method for reducing the immunogenicity of antibody variable domains
US5199942A (en)	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
LU91067I2 (en)	1991-06-14	2004-04-02	Genentech Inc	Trastuzumab and its variants and immunochemical derivatives including immotoxins
ES2136092T3 (en)	1991-09-23	1999-11-16	Medical Res Council	PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
GB9125768D0 (en)	1991-12-04	1992-02-05	Hale Geoffrey	Therapeutic method
JP4157160B2 (en)	1991-12-13	2008-09-24	ゾーマテクノロジーリミテッド	Methods for the preparation of modified antibody variable regions
GB9203459D0 (en)	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
IL104570A0 (en)	1992-03-18	1993-05-13	Yeda Res & Dev	Chimeric genes and cells transformed therewith
US8211422B2 (en)	1992-03-18	2012-07-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric receptor genes and cells transformed therewith
US5350674A (en)	1992-09-04	1994-09-27	Becton, Dickinson And Company	Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US7211259B1 (en)	1993-05-07	2007-05-01	Immunex Corporation	4-1BB polypeptides and DNA encoding 4-1BB polypeptides
EP0719329B1 (en)	1993-09-16	2010-01-06	Indiana University Research and Technology Corporation	Human receptor h4-1bb
CA2175215C (en)	1993-11-19	2008-06-03	Yat Sun Or	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
AU687491B2 (en)	1993-12-17	1998-02-26	Novartis Ag	Rapamycin derivatives useful as immunosuppressants
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
DE69528894T2 (en)	1994-05-02	2003-03-27	Bernd Groner	BIFUNCTIONAL PROTEIN, PRODUCTION AND USE
US7175843B2 (en)	1994-06-03	2007-02-13	Genetics Institute, Llc	Methods for selectively stimulating proliferation of T cells
US5786464C1 (en)	1994-09-19	2012-04-24	Gen Hospital Corp	Overexpression of mammalian and viral proteins
US5712149A (en)	1995-02-03	1998-01-27	Cell Genesys, Inc.	Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en)	1995-02-06	2000-08-15	Cell Genesys, Inc.	Multispecific chimeric receptors
NZ337002A (en)	1995-02-24	2005-07-29	Gen Hospital Corp	Redirection of cellular immunity by receptor chimeras
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6692964B1 (en)	1995-05-04	2004-02-17	The United States Of America As Represented By The Secretary Of The Navy	Methods for transfecting T cells
US7067318B2 (en)	1995-06-07	2006-06-27	The Regents Of The University Of Michigan	Methods for transfecting T cells
CN1124276C (en)	1995-06-09	2003-10-15	诺瓦蒂斯有限公司	Rapamycin derivatives
FR2736550B1 (en)	1995-07-14	1998-07-24	Sandoz Sa	PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID DISPERSION COMPRISING A MACROLIDE AND A VEHICLE
GB9526131D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Recombinant chimeric receptors
AU731826B2 (en)	1996-02-28	2001-04-05	Ariad Pharmaceuticals, Inc.	Synthetic Multimerizing Agents
US5874240A (en)	1996-03-15	1999-02-23	Human Genome Sciences, Inc.	Human 4-1BB receptor splicing variant
EP0937082A2 (en)	1996-07-12	1999-08-25	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
DE69738749D1 (en)	1996-08-16	2008-07-17	Schering Corp	CELL SURFACE ANTIGEN FROM MAMMALS AND RELATED REAGENTS
US6111090A (en)	1996-08-16	2000-08-29	Schering Corporation	Mammalian cell surface antigens; related reagents
US6114148C1 (en)	1996-09-20	2012-05-01	Gen Hospital Corp	High level expression of proteins
AU744160B2 (en)	1996-10-25	2002-02-14	Cell Genesys, Inc.	Targeted cytolysis of cancer cells
US6673901B2 (en)	1997-06-12	2004-01-06	Research Corporation Technologies, Inc.	Artificial antibody polypeptides
GB9713473D0 (en)	1997-06-25	1997-09-03	Celltech Therapeutics Ltd	Biological products
US20030060444A1 (en)	1997-06-25	2003-03-27	Celltech Therapeutics, Ltd.	Cell activation process and reagents therefor
EP1017716A4 (en) *	1997-09-19	2001-01-03	Gen Hospital Corp	CAR RECEPTORS, RELATED MOLECULES AND METHODS
US6015815A (en)	1997-09-26	2000-01-18	Abbott Laboratories	Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en)	1997-09-26	2003-10-11	Abbott Lab	Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
EP1025228A4 (en)	1997-10-21	2002-09-18	Human Genome Sciences Inc	Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
JP2001521008A (en)	1997-10-28	2001-11-06	ユニバーシティ・オブ・ブリティッシュ・コロンビア	Immune composition for promoting nerve regeneration by transiently altering central nervous system myelin in mammals and method of using same
IL137409A0 (en)	1998-02-09	2001-07-24	Genentech Inc	Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
US20040040047A1 (en)	1998-03-30	2004-02-26	Spencer David M.	Regulated apoptosis using chemically induced dimerization of apoptosis factors
DE69925909T2 (en)	1998-04-15	2006-05-11	Brigham & Women's Hospital, Inc., Boston	T-cell inhibiting receptor compositions and their use
GB9809658D0 (en)	1998-05-06	1998-07-01	Celltech Therapeutics Ltd	Biological products
EP1109921A4 (en)	1998-09-04	2002-08-28	Sloan Kettering Inst Cancer	FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE
WO2000023573A2 (en)	1998-10-20	2000-04-27	City Of Hope	Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
WO2000063374A1 (en)	1999-04-16	2000-10-26	Celltech Therapeutics Limited	Synthetic transmembrane components
AU6085700A (en)	1999-07-12	2001-01-30	Genentech Inc.	Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
EP1212331B1 (en)	1999-08-24	2004-04-21	Ariad Gene Therapeutics, Inc.	28-epirapalogs
EP1235842A4 (en)	1999-10-15	2003-04-23	Univ Massachusetts	GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE
GB9925848D0 (en)	1999-11-01	1999-12-29	Celltech Therapeutics Ltd	Biological products
US6326193B1 (en)	1999-11-05	2001-12-04	Cambria Biosciences, Llc	Insect control agent
EP1230394A4 (en)	1999-11-10	2002-12-18	Uab Research Foundation	Lentiviral vector transduction of hematopoietic stem cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US6797514B2 (en)	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
EP1257632B1 (en)	2000-02-24	2007-09-12	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US6867041B2 (en)	2000-02-24	2005-03-15	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
IL136511A0 (en)	2000-06-01	2001-06-14	Gavish Galilee Bio Appl Ltd	Genetically engineered mhc molecules
WO2001096584A2 (en)	2000-06-12	2001-12-20	Akkadix Corporation	Materials and methods for the control of nematodes
GB0025307D0 (en)	2000-10-16	2000-11-29	Celltech Chiroscience Ltd	Biological products
JP5312721B2 (en)	2000-11-07	2013-10-09	シティ・オブ・ホープ	CD19-specific redirecting immune cells
US7070995B2 (en)	2001-04-11	2006-07-04	City Of Hope	CE7-specific redirected immune cells
CN1294148C (en)	2001-04-11	2007-01-10	中国科学院遗传与发育生物学研究所	Single-stranded cyctic trispecific antibody
US20090257994A1 (en)	2001-04-30	2009-10-15	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
AU2002256390B2 (en)	2001-04-30	2007-08-30	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en)	2001-04-30	2009-04-07	City Of Hope	Chimeric immunoreceptor useful in treating human gliomas
US20030148982A1 (en)	2001-11-13	2003-08-07	Brenner Malcolm K.	Bi-spcific chimeric T cells
US7638326B2 (en)	2002-01-03	2009-12-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform
US7638325B2 (en)	2002-01-03	2009-12-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en)	2002-01-03	2010-06-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
JP4547911B2 (en)	2002-02-01	2010-09-22	アリアド・ファーマシューティカルズ・インコーポレイテッド	Phosphorus-containing compounds and uses thereof
GB0208104D0 (en)	2002-04-09	2002-05-22	Univ Dundee	Method
US7446190B2 (en)	2002-05-28	2008-11-04	Sloan-Kettering Institute For Cancer Research	Nucleic acids encoding chimeric T cell receptors
ES2263984T3 (en) *	2002-06-28	2006-12-16	Domantis Limited	DOUBLE-SPECIFIC LINKS WITH AN INCREASED SERIOUS MIDDLE LIFE.
US20040047858A1 (en)	2002-09-11	2004-03-11	Blumberg Richard S.	Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
EP1576014B1 (en)	2002-12-23	2011-06-29	Wyeth LLC	Antibodies against pd-1 and uses thereof
US20050129671A1 (en)	2003-03-11	2005-06-16	City Of Hope	Mammalian antigen-presenting T cells and bi-specific T cells
US7402431B2 (en)	2004-03-01	2008-07-22	Immunovative Therapies, Ltd.	T-cell therapy formulation
AU2004244626A1 (en)	2003-05-23	2004-12-09	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
JP5026072B2 (en)	2003-07-01	2012-09-12	イミューノメディクス、インコーポレイテッド	Multispecific carrier of bispecific antibody
US20050048054A1 (en)	2003-07-11	2005-03-03	Shino Hanabuchi	Lymphocytes; methods
EP1660186B1 (en)	2003-08-18	2013-12-25	MedImmune, LLC	Humanization of antibodies
WO2005019429A2 (en)	2003-08-22	2005-03-03	Potentia Pharmaceuticals, Inc.	Compositions and methods for enhancing phagocytosis or phagocyte activity
AU2004280333A1 (en)	2003-08-22	2005-04-21	Medimmune, Llc	Humanization of antibodies
US20050113564A1 (en)	2003-11-05	2005-05-26	St. Jude Children's Research Hospital	Chimeric receptors with 4-1BB stimulatory signaling domain
US7435596B2 (en)	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
US7220755B2 (en)	2003-11-12	2007-05-22	Biosensors International Group, Ltd.	42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
EP1692318A4 (en)	2003-12-02	2008-04-02	Genzyme Corp	Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en)	2004-04-30	2004-06-09	Isis Innovation	Method of generating improved immune response
ES2653570T3 (en)	2004-05-27	2018-02-07	The Trustees Of The University Of Pennsylvania	Innovative artificial antigen presenting cells and uses thereof
WO2006083289A2 (en)	2004-06-04	2006-08-10	Duke University	Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
JP2008512352A (en)	2004-07-17	2008-04-24	イムクローンシステムズインコーポレイティド	Novel tetravalent bispecific antibody
US7994298B2 (en)	2004-09-24	2011-08-09	Trustees Of Dartmouth College	Chimeric NK receptor and methods for treating cancer
ES2766123T3 (en)	2004-12-10	2020-06-11	Peter Maccallum Cancer Inst	Methods and compositions for adoptive immunotherapy
PT2343320T (en)	2005-03-25	2018-01-23	Gitr Inc	Anti-gitr antibodies and uses thereof
CN103059138B (en)	2005-05-09	2015-10-28	小野药品工业株式会社	The human monoclonal antibodies of programmed death-1 (PD-1) and use anti-PD-1 antibody to carry out the method for Therapeutic cancer
EP3805245A1 (en)	2005-05-17	2021-04-14	University of Connecticut	Compositions and methods for immunomodulation in an organism
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
ME02260B (en)	2005-07-01	2016-02-29	Medarex Inc	HUMAN MONOCLONAL ANTIBODIES AGAINST A PROGRAMMED TYPE 1 DEATH LIGAND (PD-L1)
US20070036773A1 (en)	2005-08-09	2007-02-15	City Of Hope	Generation and application of universal T cells for B-ALL
CN101370525B (en)	2005-08-19	2013-09-18	Abbvie公司	Dual variable domain immunoglobin and uses thereof
WO2007044729A2 (en)	2005-10-07	2007-04-19	Exelixis, Inc.	N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
US9303080B2 (en)	2006-01-13	2016-04-05	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health	Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
EP1981969A4 (en)	2006-01-19	2009-06-03	Genzyme Corp	Gitr antibodies for the treatment of cancer
WO2008045437A2 (en)	2006-10-09	2008-04-17	The General Hospital Corporation	Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
EP1916259A1 (en)	2006-10-26	2008-04-30	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
US20080131415A1 (en)	2006-11-30	2008-06-05	Riddell Stanley R	Adoptive transfer of cd8 + t cell clones derived from central memory cells
CA2584494A1 (en)	2007-03-27	2008-09-27	Jeffrey A. Medin	Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
JP5840837B2 (en)	2007-03-30	2016-01-06	メモリアルスローン−ケタリングキャンサーセンター	Constitutive expression of costimulatory ligands in adoptively transferred T lymphocytes
HRP20131167T1 (en)	2007-06-18	2014-01-03	Merck Sharp & Dohme B.V.	HUMAN RECEPTOR PROGRAMMED DEATHS ANTIBODIES PD-1
NZ599338A (en)	2007-06-27	2013-11-29	Marinepolymer Tech Inc	Complexes of il-15 and il-15ralpha and uses thereof
CA2693677C (en)	2007-07-12	2018-02-13	Tolerx, Inc.	Combination therapies employing gitr binding molecules
CA2703947C (en)	2007-10-26	2018-12-04	Governing Council Of The University Of Toronto	Therapeutic and diagnostic methods using tim-3
WO2009091826A2 (en)	2008-01-14	2009-07-23	The Board Of Regents Of The University Of Texas System	Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2009097140A1 (en)	2008-01-30	2009-08-06	Memorial Sloan-Kettering Cancer Center	Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
WO2009101611A1 (en)	2008-02-11	2009-08-20	Curetech Ltd.	Monoclonal antibodies for tumor treatment
CN102014912A (en)	2008-02-21	2011-04-13	阿斯利康(瑞典)有限公司	Combination therapy 238
US8379824B2 (en)	2008-03-06	2013-02-19	At&T Intellectual Property I, Lp	Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
WO2009114335A2 (en)	2008-03-12	2009-09-17	Merck & Co., Inc.	Pd-1 binding proteins
CA2729810A1 (en)	2008-07-02	2010-01-07	Emergent Product Development Seattle, Llc	Tgf-.beta. antagonist multi-target binding proteins
AR072999A1 (en)	2008-08-11	2010-10-06	Medarex Inc	HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
EP2328920A2 (en)	2008-08-25	2011-06-08	Amplimmune, Inc.	Targeted costimulatory polypeptides and methods of use to treat cancer
AU2009288730B2 (en)	2008-08-25	2013-06-20	Amplimmune, Inc.	Compositions of PD-1 antagonists and methods of use
PT3006459T (en)	2008-08-26	2021-11-26	Hope City	Method and compositions for enhanced anti-tumor effector functioning of t cells
US8586023B2 (en)	2008-09-12	2013-11-19	Mie University	Cell capable of expressing exogenous GITR ligand
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
MY188826A (en)	2008-12-09	2022-01-06	Genentech Inc	Anti-pd-l1 antibodies and their use to enhance t-cell function
US9206440B2 (en)	2009-01-23	2015-12-08	Roger Williams Hospital	Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
US8383778B2 (en)	2009-01-29	2013-02-26	Abbvie Inc.	IL-1 binding proteins
EP3192811A1 (en)	2009-02-09	2017-07-19	Université d'Aix-Marseille	Pd-1 antibodies and pd-l1 antibodies and uses thereof
MX2011008843A (en)	2009-02-23	2011-12-14	Glenmark Pharmaceuticals Sa	Humanized antibodies that bind to cd19 and their uses.
JP5465318B2 (en)	2009-04-03	2014-04-09	ベラステム・インコーポレーテッド	Pyrimidine substituted purine compounds as kinase inhibitors
AU2010243211B2 (en)	2009-04-30	2014-01-30	Ramot At Tel Aviv University Ltd.	Anti CEACAM1 antibodies and methods of using same
AU2010282280B2 (en)	2009-08-14	2016-06-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of IL-15 to increase thymic output and to treat lymphopenia
EP3023438B1 (en)	2009-09-03	2020-03-11	Merck Sharp & Dohme Corp.	Anti-gitr antibodies
EP2483301A1 (en)	2009-10-01	2012-08-08	The United States Of America, As Represented By The Secretary, Department of Health and Human Services	Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9181527B2 (en)	2009-10-29	2015-11-10	The Trustees Of Dartmouth College	T cell receptor-deficient T cell compositions
GB0919054D0 (en)	2009-10-30	2009-12-16	Isis Innovation	Treatment of obesity
PT2496698T (en) *	2009-11-03	2019-04-18	Hope City	TRUNCED EPIDERMAL GROWTH FACTOR RECEIVER (EGFRT) FOR SELECTION OF TRANSDUCED T CELLS
US8956828B2 (en)	2009-11-10	2015-02-17	Sangamo Biosciences, Inc.	Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
JP2013512251A (en)	2009-11-24	2013-04-11	アンプリミューン、インコーポレーテッド	Simultaneous inhibition of PD-L1 / PD-L2
CN105693861A (en)	2009-12-29	2016-06-22	新兴产品开发西雅图有限公司	Heterodimer binding protein and application thereof
WO2011097477A1 (en)	2010-02-04	2011-08-11	The Trustees Of The University Of Pennsylvania	Icos critically regulates the expansion and function of inflammatory human th17 cells
US9089520B2 (en)	2010-05-21	2015-07-28	Baylor College Of Medicine	Methods for inducing selective apoptosis
CA2802344C (en)	2010-06-18	2023-06-13	The Brigham And Women's Hospital, Inc.	Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2011160119A2 (en) *	2010-06-19	2011-12-22	Memorial Sloan-Kettering Cancer Center	Anti-gd2 antibodies
CA2803900A1 (en)	2010-07-09	2012-01-12	Exelixis, Inc.	Combinations of kinase inhibitors for the treatment of cancer
WO2012007926A1 (en)	2010-07-16	2012-01-19	Piramal Life Sciences Limited	Substituted imidazoquinoline derivatives as kinase inhibitors
CA2993567C (en)	2010-07-21	2022-06-28	Sangamo Biosciences, Inc.	Methods and compositions for modification of a t-cell receptor gene
WO2012050374A2 (en) *	2010-10-13	2012-04-19	Innocell, Inc.	Immunotherapy for solid tumors
WO2012058460A2 (en)	2010-10-27	2012-05-03	Baylor College Of Medicine	Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
EP3693017A1 (en)	2010-12-14	2020-08-12	University of Maryland, Baltimore	Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
SG192010A1 (en)	2011-01-18	2013-08-30	Univ Pennsylvania	Compositions and methods for treating cancer
KR101440529B1 (en) *	2011-03-18	2014-09-17	주식회사 엘지화학	Method of preparing dinitrile compounds
CN106074601A (en)	2011-03-23	2016-11-09	弗雷德哈钦森癌症研究中心	Method and composition for cellular immunotherapy
WO2012127464A2 (en)	2011-03-23	2012-09-27	Gavish-Galilee Bio Applications Ltd	Constitutively activated t cells for use in adoptive cell therapy
AU2012236068A1 (en)	2011-04-01	2013-10-17	Eureka Therapeutics, Inc.	T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
NZ616405A (en)	2011-04-08	2015-11-27	Baylor College Medicine	Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
IL285335B2 (en)	2011-04-08	2023-12-01	Us Health	Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
US20130071414A1 (en)	2011-04-27	2013-03-21	Gianpietro Dotti	Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US8841418B2 (en)	2011-07-01	2014-09-23	Cellerant Therapeutics, Inc.	Antibodies that specifically bind to TIM3
EP4488370A2 (en)	2011-07-25	2025-01-08	Nationwide Children's Hospital, Inc.	Recombinant virus products and methods for inhibition of expresssion of dux4
EA201490364A1 (en)	2011-07-29	2014-08-29	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	COSTIMULATING SWITCHING RECEPTORS
RU2636588C2 (en)	2011-08-11	2017-11-24	ИНТЕЛЛАЙКИН, ЭлЭлСи	Polymorphs of kinase inhibitor
US9833476B2 (en)	2011-08-31	2017-12-05	The Trustees Of Dartmouth College	NKP30 receptor targeted therapeutics
WO2013039954A1 (en)	2011-09-14	2013-03-21	Sanofi	Anti-gitr antibodies
MX2014003176A (en)	2011-09-16	2015-08-05	Univ Pennsylvania	T-CELLS DESIGNED BY ARN FOR CANCER TREATMENT.
EP3326467B1 (en)	2011-09-16	2020-03-11	Baylor College of Medicine	Targeting the tumor microenvironment using manipulated nkt cells
WO2013054320A1 (en)	2011-10-11	2013-04-18	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
KR20230109775A (en) *	2011-10-19	2023-07-20	파마싸이클릭스 엘엘씨	Use of inhibitors of bruton's tyrosine kinase (btk)
ES2654060T3 (en)	2011-10-20	2018-02-12	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Anti-CD22 chimeric antigen receptors
US20130131139A1 (en) *	2011-11-17	2013-05-23	Oregon Health & Science University	Ror1 as a gene target in acute lymphoblastic leukemia
CA2892371C (en)	2011-12-01	2021-01-19	The Brigham And Women's Hospital, Inc.	Anti-ceacam1 recombinant antibodies for cancer therapy
EP2817331B1 (en)	2012-02-22	2023-08-30	The Trustees of the University of Pennsylvania	Use of the cd2 signaling domain in second-generation chimeric antigen receptors
MX2014010181A (en)	2012-02-22	2015-03-20	Univ Pennsylvania	Use of icos-based cars to enhance antitumor activity and car persistence.
CA2863799C (en)	2012-02-22	2020-09-01	Matthew J. FRIGAULT	Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
LT2800811T (en)	2012-05-25	2017-09-11	The Regents Of The University Of California	Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
KR20150030724A (en)	2012-07-13	2015-03-20	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	Compositions and methods for regulating car t cells
HUE048947T2 (en)	2012-07-13	2020-09-28	Univ Pennsylvania	Toxicity management of the antitumor effect of CARs
IN2015DN00139A (en)	2012-07-13	2015-06-12	Univ Pennsylvania
WO2014011993A2 (en)	2012-07-13	2014-01-16	The Trustees Of The University Of Pennsylvania	Epitope spreading associated with car t-cells
US9765156B2 (en)	2012-07-13	2017-09-19	The Trustees Of The University Of Pennsylvania	Enhancing activity of CAR T cells by co-introducing a bispecific antibody
EP3584256A1 (en)	2012-07-13	2019-12-25	The Trustees Of The University Of Pennsylvania	Methods of assessing the suitability of transduced t cells for administration
EP2879709B1 (en)	2012-07-31	2020-01-08	The Brigham and Women's Hospital, Inc.	Modulation of the immune response
US10780118B2 (en)	2012-08-20	2020-09-22	Fred Hutchinson Cancer Research Center	Method and compositions for cellular immunotherapy
US9937205B2 (en)	2012-09-04	2018-04-10	The Trustees Of The University Of Pennsylvania	Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
EP2904106A4 (en)	2012-10-01	2016-05-11	Univ Pennsylvania	COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER
US10117896B2 (en)	2012-10-05	2018-11-06	The Trustees Of The University Of Pennsylvania	Use of a trans-signaling approach in chimeric antigen receptors
CA3201072A1 (en)	2012-10-12	2014-04-17	The Brigham And Women's Hospital, Inc.	Enhancement of the immune response
CN110982844B (en)	2012-12-12	2024-08-13	布罗德研究所有限公司	CRISPR-CAS component systems, methods, and compositions for sequence manipulation
US8697359B1 (en)	2012-12-12	2014-04-15	The Broad Institute, Inc.	CRISPR-Cas systems and methods for altering expression of gene products
ES2576126T3 (en)	2012-12-12	2016-07-05	The Broad Institute, Inc.	Modification by genetic technology and optimization of improved enzyme systems, methods and compositions for sequence manipulation
EP2943565B1 (en)	2013-01-14	2018-03-28	Fred Hutchinson Cancer Research Center	Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
HUE036250T2 (en)	2013-02-15	2018-06-28	Univ California	Chimeric antigen receptor and methods for its use
PL2958943T3 (en)	2013-02-20	2020-04-30	The Trustees Of The University Of Pennsylvania	Treatment of malignant neoplasm with a humanized chimeric anti-egfrviii antigen receptor
US9573988B2 (en)	2013-02-20	2017-02-21	Novartis Ag	Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9434935B2 (en)	2013-03-10	2016-09-06	Bellicum Pharmaceuticals, Inc.	Modified caspase polypeptides and uses thereof
US9944690B2 (en)	2013-03-14	2018-04-17	Bellicum Pharmaceuticals, Inc.	Methods for controlling T cell proliferation
US9657105B2 (en) *	2013-03-15	2017-05-23	City Of Hope	CD123-specific chimeric antigen receptor redirected T cells and methods of their use
ES2769574T3 (en)	2013-03-15	2020-06-26	Michael C Milone	Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (en) *	2013-03-16	2019-03-21	諾華公司	Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
DK3004329T3 (en)	2013-06-05	2020-05-18	Bellicum Pharmaceuticals Inc	METHODS FOR INDUCTION OF PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES
ES2741308T3 (en) *	2013-10-15	2020-02-10	Scripps Research Inst	T-cell switches with chimeric antigen receptors and uses thereof
US9512084B2 (en)	2013-11-29	2016-12-06	Novartis Ag	Amino pyrimidine derivatives
PE20210648A1 (en) *	2013-12-17	2021-03-26	Genentech Inc	ANTI-CD3 ANTIBODIES AND METHODS OF USE
TWI672379B (en)	2013-12-19	2019-09-21	瑞士商諾華公司	Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en)	2013-12-20	2024-06-05	Novartis AG	Regulatable chimeric antigen receptor
EP3097117B1 (en)	2014-01-21	2023-10-04	Novartis Ag	Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
ES2939760T3 (en)	2014-03-15	2023-04-26	Novartis Ag	Cancer treatment using a chimeric receptor for antigens
EP3119425B1 (en)	2014-03-15	2020-09-23	Novartis AG	Regulatable chimeric antigen receptor
US9775844B2 (en) *	2014-03-19	2017-10-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
DK3888674T3 (en)	2014-04-07	2024-07-08	Novartis Ag	TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
US20170226495A1 (en)	2014-07-21	2017-08-10	Novartis Ag	Sortase molecules and uses thereof
US20170274014A1 (en)	2014-07-21	2017-09-28	Jennifer Brogdon	Combinations of low, immune enhancing, doses of mtor inhibitors and cars
WO2016014553A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Sortase synthesized chimeric antigen receptors
EP3193915A1 (en)	2014-07-21	2017-07-26	Novartis AG	Combinations of low, immune enhancing. doses of mtor inhibitors and cars
CA2955154C (en)	2014-07-21	2023-10-31	Novartis Ag	Treatment of cancer using a cd33 chimeric antigen receptor
EP3172237A2 (en)	2014-07-21	2017-05-31	Novartis AG	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
KR20170037625A (en)	2014-07-21	2017-04-04	노파르티스 아게	Treatment of cancer using a cll-1 chimeric antigen receptor
EP3660042B1 (en)	2014-07-31	2023-01-11	Novartis AG	Subset-optimized chimeric antigen receptor-containing t-cells
CA2958200A1 (en)	2014-08-14	2016-02-18	Novartis Ag	Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
EP3712171A1 (en)	2014-08-19	2020-09-23	Novartis AG	Treatment of cancer using a cd123 chimeric antigen receptor
KR102804360B1 (en)	2014-09-17	2025-05-12	노파르티스 아게	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
RU2743657C2 (en)	2014-10-08	2021-02-20	Новартис Аг	Biomarkers predicting a therapeutic response to therapy with a chimeric antigen receptor, and use thereof
WO2016061368A1 (en)	2014-10-15	2016-04-21	The Children's Hospital Of Philadelphia	Compositions and methods for treating b-lymphoid malignancies
AU2015374296B2 (en)	2014-12-29	2021-09-02	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en)	2015-01-16	2016-07-21	Novartis Pharma Ag	Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
US20180140602A1 (en)	2015-04-07	2018-05-24	Novartis Ag	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
HUE059218T2 (en)	2015-04-08	2022-11-28	Novartis Ag	Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
ES2948133T3 (en)	2015-04-17	2023-08-31	Novartis Ag	Methods to improve the efficiency and expansion of cells expressing a chimeric antigen receptor
WO2016172583A1 (en)	2015-04-23	2016-10-27	Novartis Ag	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TWI859112B (en)	2015-07-21	2024-10-21	瑞士商諾華公司	Methods for improving the efficacy and expansion of immune cells
EP3331913A1 (en)	2015-08-07	2018-06-13	Novartis AG	Treatment of cancer using chimeric cd3 receptor proteins
CN108780084B (en)	2015-09-03	2022-07-22	诺华股份有限公司	Biomarkers predictive of cytokine release syndrome
SG10202110257UA (en)	2015-09-17	2021-10-28	Novartis Ag	Car t cell therapies with enhanced efficacy
JP7118887B2 (en) *	2015-11-23	2022-08-16	ノバルティスアーゲー	Optimized lentiviral transfer vectors and their uses
KR102717188B1 (en) *	2016-10-07	2024-10-16	노파르티스 아게	Chimeric antigen receptors for the treatment of cancer
US20210396739A1 (en) *	2018-05-01	2021-12-23	Novartis Ag	Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) *	2018-05-25	2019-11-28	Novartis Ag	Combination therapy with chimeric antigen receptor (car) therapies
AR116109A1 (en) *	2018-07-10	2021-03-31	Novartis Ag	DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
CN112261970B (en) *	2018-07-10	2025-02-07	诺华股份有限公司	3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in treating IKAROS family zinc finger 2 (IKZF2) dependent diseases
AR120566A1 (en) *	2019-11-26	2022-02-23	Novartis Ag	CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
AR120563A1 (en) *	2019-11-26	2022-02-23	Novartis Ag	CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
CN116635062A (en) *	2020-11-13	2023-08-22	诺华股份有限公司	Combination Therapies Using Cells Expressing Chimeric Antigen Receptors (CARs)

2015
- 2015-04-07 DK DK21160203.2T patent/DK3888674T3/en active
- 2015-04-07 TW TW104111176A patent/TWI753848B/en active
- 2015-04-07 ES ES21160203T patent/ES2988631T3/en active Active
- 2015-04-07 HU HUE21160203A patent/HUE066973T2/en unknown
- 2015-04-07 FI FIEP21160203.2T patent/FI3888674T3/en active
- 2015-04-07 US US14/680,860 patent/US10357514B2/en active Active
- 2015-04-07 LT LTEP15719043.0T patent/LT3129470T/en unknown
- 2015-04-07 RU RU2016142896A patent/RU2718542C2/en active
- 2015-04-07 EP EP24166976.1A patent/EP4406610A3/en active Pending
- 2015-04-07 CA CA2940671A patent/CA2940671A1/en active Pending
- 2015-04-07 KR KR1020167027427A patent/KR102487608B1/en active Active
- 2015-04-07 PL PL21160203.2T patent/PL3888674T3/en unknown
- 2015-04-07 SI SI201531647T patent/SI3129470T1/en unknown
- 2015-04-07 MY MYPI2016702996A patent/MY191608A/en unknown
- 2015-04-07 ES ES15719043T patent/ES2876263T3/en active Active
- 2015-04-07 MX MX2016013239A patent/MX395149B/en unknown
- 2015-04-07 EP EP15719043.0A patent/EP3129470B1/en active Active
- 2015-04-07 HR HRP20240874TT patent/HRP20240874T1/en unknown
- 2015-04-07 KR KR1020237000827A patent/KR102651707B1/en active Active
- 2015-04-07 HU HUE15719043A patent/HUE054588T2/en unknown
- 2015-04-07 CN CN202010128384.0A patent/CN111514283A/en active Pending
- 2015-04-07 AU AU2015244039A patent/AU2015244039B2/en active Active
- 2015-04-07 KR KR1020247009639A patent/KR20240042250A/en not_active Ceased
- 2015-04-07 PL PL15719043T patent/PL3129470T3/en unknown
- 2015-04-07 SI SI201532018T patent/SI3888674T1/en unknown
- 2015-04-07 SG SG11201606909RA patent/SG11201606909RA/en unknown
- 2015-04-07 IL IL280215A patent/IL280215B/en unknown
- 2015-04-07 PT PT211602032T patent/PT3888674T/en unknown
- 2015-04-07 IL IL293603A patent/IL293603B2/en unknown
- 2015-04-07 PT PT157190430T patent/PT3129470T/en unknown
- 2015-04-07 IL IL307423A patent/IL307423A/en unknown
- 2015-04-07 JP JP2016561313A patent/JP6765966B2/en active Active
- 2015-04-07 LT LTEP21160203.2T patent/LT3888674T/en unknown
- 2015-04-07 WO PCT/US2015/024671 patent/WO2015157252A1/en active Application Filing
- 2015-04-07 HR HRP20211055TT patent/HRP20211055T1/en unknown
- 2015-04-07 CN CN201580018102.9A patent/CN107075482B/en active Active
- 2015-04-07 EP EP21160203.2A patent/EP3888674B1/en active Active
- 2015-04-07 DK DK15719043.0T patent/DK3129470T3/en active
- 2015-04-07 SG SG10202109752X patent/SG10202109752XA/en unknown
2016
- 2016-08-10 IL IL247204A patent/IL247204B/en active IP Right Grant
- 2016-08-16 ZA ZA2016/05657A patent/ZA201605657B/en unknown
- 2016-10-07 MX MX2022010623A patent/MX2022010623A/en unknown
2019
- 2019-06-07 US US16/435,257 patent/US20190388471A1/en active Pending
2020
- 2020-03-11 JP JP2020041499A patent/JP7258802B2/en active Active
2022
- 2022-01-18 AU AU2022200288A patent/AU2022200288B2/en active Active
2023
- 2023-04-05 JP JP2023061386A patent/JP2023085460A/en active Pending
2025
- 2025-02-07 AU AU2025200842A patent/AU2025200842A1/en active Pending

Also Published As

Publication number	Publication date
IL293603B2 (en)	2024-03-01
LT3129470T (en)	2021-07-12
TW201600092A (en)	2016-01-01
AU2022200288A1 (en)	2022-02-10
JP7258802B2 (en)	2023-04-17
KR102651707B1 (en)	2024-03-29
EP4406610A3 (en)	2024-10-30
CN107075482B (en)	2021-03-16
IL247204A0 (en)	2016-09-29
KR20160135233A (en)	2016-11-25
US10357514B2 (en)	2019-07-23
IL293603B1 (en)	2023-11-01
WO2015157252A1 (en)	2015-10-15
BR112016022798A2 (en)	2017-10-17
SG11201606909RA (en)	2016-10-28
PT3129470T (en)	2021-07-13
KR20230012658A (en)	2023-01-26
PL3888674T3 (en)	2024-09-23
ES2876263T3 (en)	2021-11-12
PT3888674T (en)	2024-07-09
CN111514283A (en)	2020-08-11
RU2020110834A (en)	2020-04-27
IL293603A (en)	2022-08-01
SI3888674T1 (en)	2024-08-30
JP2023085460A (en)	2023-06-20
DK3129470T3 (en)	2021-07-05
SI3129470T1 (en)	2021-08-31
PL3129470T3 (en)	2021-11-29
HUE054588T2 (en)	2021-09-28
EP3888674B1 (en)	2024-04-03
RU2016142896A3 (en)	2019-01-25
KR102487608B1 (en)	2023-01-12
TWI753848B (en)	2022-02-01
CA2940671A1 (en)	2015-10-15
JP6765966B2 (en)	2020-10-07
AU2015244039A1 (en)	2016-09-15
ZA201605657B (en)	2023-10-25
AU2025200842A1 (en)	2025-02-27
LT3888674T (en)	2024-07-25
IL307423A (en)	2023-12-01
AU2015244039B2 (en)	2021-10-21
JP2017517488A (en)	2017-06-29
DK3888674T3 (en)	2024-07-08
IL280215A (en)	2021-03-01
MX395149B (en)	2025-03-24
HRP20211055T1 (en)	2021-10-01
EP3129470B1 (en)	2021-04-07
EP3888674A1 (en)	2021-10-06
ES2988631T3 (en)	2024-11-21
CN107075482A (en)	2017-08-18
AU2022200288B2 (en)	2024-11-07
WO2015157252A8 (en)	2016-08-04
MY191608A (en)	2022-07-01
IL247204B (en)	2021-02-28
FI3888674T3 (en)	2024-07-02
EP4406610A2 (en)	2024-07-31
EP3129470A1 (en)	2017-02-15
HRP20240874T1 (en)	2024-10-11
US20190388471A1 (en)	2019-12-26
HUE066973T2 (en)	2024-09-28
US20150283178A1 (en)	2015-10-08
MX2022010623A (en)	2022-10-07
RU2016142896A (en)	2018-05-07
JP2020121975A (en)	2020-08-13
IL280215B (en)	2022-07-01
MX2016013239A (en)	2017-05-03
RU2718542C2 (en)	2020-04-08
KR20240042250A (en)	2024-04-01

Publication	Publication Date	Title
IL280215A (en)	2021-03-01	Cancer treatment using chimeric antigen receptor (CAR) against CD19
IL250043B (en)	2021-06-30	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
IL265755A (en)	2019-06-30	Chimeric antigen receptors for the treatment of cancer
IL250138B (en)	2021-01-31	Treatment of cancer using a cd33 chimeric antigen receptor
IL241261B (en)	2020-02-27	Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
IL250161A0 (en)	2017-03-30	Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
IL250116A0 (en)	2017-03-30	Treatment of cancer using a cll-1 chimeric antigen receptor
IL247917A0 (en)	2016-11-30	Cd33 specific chimeric antigen receptors for cancer immunotherapy
IL250339A0 (en)	2017-03-30	Egfrviii specific chimeric antigen receptors for cancer immunotherapy
SG11201505896YA (en)	2015-09-29	Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
SG11201606790XA (en)	2016-09-29	Chimeric antigen receptor
IL246540A0 (en)	2016-08-31	Frizzled receptor antibodies for treatment of cancer
HK40107394A (en)	2024-10-18	Treatment of cancer using anti-cd19 chimeric antigen receptor
HK1240596A1 (en)	2018-05-25	Treatment of cancer using gfr alpha-4 chimeric antigen receptor
GB201409761D0 (en)	2014-07-16	Chimeric antigen receptor
GB201403481D0 (en)	2014-04-16	Chimeric antigen receptor